LMNA and familial dilated cardiomyopathy: Interestingly, the first symptomatic treatment for DCM due to Lmna mutations, like that affecting the family expressing LMNA R321X, is based on the use of anti-hypertensive drug such as β-blockers and ACE inhibitors [4], thus suggesting that the use of guanabenz could be in line with the currently used therapeutic management of cardiac laminopathies.